Fingolimod (Gilenya)

Drug Name: Fingolimod (Gilenya)
Company: ALS Therapy Development Institute
Location: US-Massachusetts
Website: http://www.als.net
Drug Type: Small molecule
Conditions: ALS
Mechanism Type: Immunomodulation
Mechanism: TDI-132 (aka: fingolimod/ Novartis’ drug Gilenya) is an agonist of the sphigosine 1 phosphate receptor.It blocks T-cell infiltration into the CNS by reducing their circulation in the blood and retaining them in the lymph nodes. The drug is being developed to reduce neuroinflammation associated with disease progression in ALS.
U.S. Status for ALS: Inactive

References:
[1] Fingolimod (Gilenya, TDI 132). ALS Therapy Development Institute, 2016. Accessed 9 Mar 2016 from http://www.alstdi.org/als-research/als-topics/gilenya/.

Last updated March 9th, 2016

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail